Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLM 10 is a selective tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50 values are 0.62 and 2 μM for human and mouse TDO, respectively). Exhibits selectivity for TDO over IDO, MAO-A, MAO-B, and a panel of receptors and transporters. Reduces growth of TDO-expressing P815 mastocytoma tumors in mice. Orally bioavailable.
分子量 | 229.21 |
公式 | C11H8FN5 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1316695-35-8 |
PubChem ID | 91885138 |
InChI Key | FSGAFWYMLAWNJM-UHFFFAOYSA-N |
Smiles | FC1=CC=C2C(NC=C2/C=C/C3=NN=NN3)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Pilotte et al (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc.Natl.Acad.Sci.U.S.A. 109 2497 PMID: 22308364
Dolusić et al (2011) Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J.Med.Chem. 54 5320 PMID: 21726069
关键词: LM 10, LM 10 supplier, LM10, selective, 2,3-dioxygenase, TDO, inhibitors, inhibits, orally, bioavailable, anticancer, cancer, immunology, Tryptophan, 2,3, dioxygenase, Immune, Checkpoints, 5794, Tocris Bioscience
目前没有该产品的评论。 Be the first to review LM 10 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.